News

Investigator Anita Clayton, MD, shares insights into the new vortioxetine data and its implications for patients with depression and treatment-emergent sexual dysfunction.

About half of all MS patients experience an episode of depression during their lifetimes, but most interventions are drug-related or psychiatric.

Investigators attributed 12% of the overall increase in vaccinations over a seven-week period to their notification program, when comparing to the previous year's vaccination rate.

A new study finds high-dose intravitreal triamcinolone acetonide is a safe alternative to anti-vascular endothelial growth factor, a finding that is welcome news for patients in low-income countries.

Finalizing a changing diagnosis of an epilepsy syndrome was associated with greater likelihood of a sustained seizure-free period, a new study has found.

Most of the patients in the study were taking concomitant antidepressants and/or antipsychotics, and mood disorders remained stable during treatment with valbenazine.

If CVS and Aetna are truly charting the future of healthcare in this country, then it’s long past-time that their actions align to their rhetoric.

The Spiration Valve System treats emphysema by blocking air from entering diseased areas of the lung.

Can we learn from the last flu season and prepare for the coming peak influenza activity of the current season?

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

The pressure for pharma to exist in a permanent state of innovation gets us better therapeutics, but it’s driving up costs unsustainably.

Ophthotech says it’s sidelining its Zimura/Lucentis program despite positive phase 2a results.

The non-invasive device is now the first and only FDA product approved for the prevention of cluster headache.

In this retrospective study, 18.5% of children became drug-free while on the ketogenic diet.

The findings supported the FDA approval of lanadelumab for hereditary angioedema treatment earlier this year.

Successful 8-week treatment of newly diagnosed HCV genotype 1 adds to evidence that early detection could enable shorter, less costly treatments.

A new, large cohort study has confirmed the link between conditions, which was only previously confirmed in adult patients.

The FDA has approved Dextenza, a dexamethasone ophthalmic insert, for the treatment of ocular pain following ophthalmic surgery.

How the opioid epidemic and high drug prices have brought the hepatitis C burden onto a younger population in 2018.

The FDA has accepted a Biologics License Application as well as granted Priority Review for the gene therapy that treats spinal muscular atrophy (SMA) Type 1.

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

Patients frequently report not receiving sufficient information about COPD and how to manage it, investigators noted.

While common in adults, congenital cytomegalovirus may cause problems such as hearing and vision loss in newborns.

HCV RNA in peripheral blood mononuclear cells predicted relapse of HCV genotype 4 in cirrhotic patients who were non-viremic after treatment.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

New research suggests HCV coinfection is dangerous for pregnant women with HIV.

Investigators test methods of incorporating smaller, localized datasets to improve influenza outbreak forecasts and increase community preparedness.

New trial results show adding ribavirin to a sofosbuvir plus velpatasvir regimen is beneficial for the considered difficult-to-reach patient population.